Entering text into the input field will update the search result below

Weather The Fed With AbbVie's Strong Portfolio And Solid Dividend Growth

Mar. 14, 2023 7:44 AM ETAbbVie Inc. (ABBV)13 Comments
Value Prof profile picture
Value Prof


  • AbbVie's Humira sales may hold up better against biosimilars in the USA than they have in Europe.
  • The pharmaceutical giant has a diverse portfolio of blockbuster drugs that should help to offset declining revenues in its leading therapies.
  • AbbVie offers a safely growing dividend with a current yield near 4%.
  • I examine AbbVie's current outlook, dividend strength, and valuation to determine whether ABBV stock is a buy at current levels.

Cancer cells on dna stand background. 3d illustration

Mohammed Haneefa Nizamudeen

Amidst the current market turmoil largely driven by the Fed's rapid rate hike campaign and its potential near-term ramifications across the financial sector, many investors are seeking safer places for their capital, both in equities and fixed income, to

ABBV Historical Dividends

ABBV Historical Dividends (dividendinvestor.com)

ABBV Payout Ratio 2013-22

ABBV Payout Ratio 2013-22 (Seeking Alpha)

ABBV Valuation

ABBV Valuation (Morningstar)

ABBV Valuation

ABBV Valuation (Seeking Alpha)

ABBV 2023 EPS Projections

ABBV 2023 EPS Projections (Seeking Alpha)

This article was written by

Value Prof profile picture
I'm Value Prof, a market researcher and former investment advisor primarily focusing on utility and consumer stocks, dividend growth strategies, and occasional swing trades. I like to highlight high-quality, undercovered companies that offer a mix of steady growth and rising income. Drawing on my professional background in finance, technology, and entertainment, I aim to help you navigate the stock market and become a smarter, happier investor by offering well-researched, independent, and often contrarian takes on the news, politics, and the macro environment.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.